| Literature DB >> 30963795 |
Qianjing Zhang1,2,3, Cuixia Di1,2,3, Junfang Yan1,2,3, Fang Wang1,2,3, Tao Qu4, Yupei Wang1,2,3, Yuhong Chen1,2,3, Xuetian Zhang1,2,3, Yang Liu1,2,3, Hongying Yang5, Hong Zhang1,2,3.
Abstract
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3b1 subunit of the spliceosome. There is considerable interest in the compound as a tool to study SF3b1 function in cancer. However, so far little information is available on the molecular mechanism of SF3b1 eliciting apoptosis in cancer cells. Here, we investigated the molecular mechanism of SF3b1 eliciting apoptosis in human cervical carcinoma cells. We demonstrated that inhibition of SF3b1 by pladienolide B inhibited proliferation of HeLa cells at low nanomolar concentrations in a dose- and time-dependent manner. It also induced G2/M phase arrest and significant rise of apoptotic cells. Moreover, it is indicated that inhibition of SF3b1 by pladienolide B induced Tap73/ΔNp73 expression and consequently down-regulated Bax/Bcl-2 ratio, cytochrome c release and caspase-3 expression. Thus, our results showed that SF3b1 plays a pivotal role in cycle arrest, apoptosis induction, and p73 splicing in human cervical carcinoma cells, suggesting that SF3b1 could be used as a potential candidate for cervical cancer therapy.Entities:
Keywords: Alternative splicing; SF3b1; apoptosis; cancer; p73; pladienolide B
Mesh:
Substances:
Year: 2019 PMID: 30963795 DOI: 10.1080/21691401.2019.1596922
Source DB: PubMed Journal: Artif Cells Nanomed Biotechnol ISSN: 2169-1401 Impact factor: 5.678